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Abstract
Background—Burkitt lymphoma (BL) occurs at all ages, but the patterns of Epstein-Barr virus 
(EBV) positivity in relation to human immunodeficiency virus (HIV), immunoprofiles and age 
have not been fully explored.
Design and methods—BL tissues from residual tissue repositories, and 2 academic centers in 
the United States were examined by expert hematopathologists for morphology, 
immunohistochemistry, MYC rearrangement, EBV early RNA (EBER), and diagnosed according 
to the 2008 WHO lymphoma classification. Analysis was done using frequency tables, Chi-
squared statistics, and Student’s t-test.
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Results—Of 117 cases examined, 91 were confirmed as BL. The age distribution was 26%, 
15%, 19%, and 29% for 0-19, 20-34, 35-59, 60+ years, and missing in 11%. MYC rearrangement 
was found in 89% and EBER positivity in 29% of 82 cases with results. EBER positivity varied 
with age (from 13% in age-group 0-19 to 55% in age-group 20-34, and fell to 25% in age-group 
60+ years, P=0.08); with race (56% in Blacks/Hispanics versus 21% in Whites/Asians/Pacific 
Islanders, P=0.006); and by HIV status (64% in HIV positive versus 22% in HIV negative cases, 
P=0.03).
Conclusions—EBER positivity was demonstrated in about one-third of tumors and it was 
strongly associated with race and HIV status, and marginally with age-group.
Introduction
Burkitt lymphoma (BL) is a rapidly growing B cell non-Hodgkin lymphoma (NHL) (1). 
First described in 1958 in African children (2), three subtypes have been described 
worldwide as endemic, sporadic, and immunodeficiency-associated BL (1). The subtypes 
are indistinguishable by routine pathology, so they are considered a single biological entity, 
albeit with distinct epidemiological patterns. Endemic BL occurs as a rapidly growing tumor 
with male preponderance involving the jaw or abdomen in children in Africa. The peak age 
is 5-9 years, and childhood exposure to Epstein-Barr virus (EBV) and Plasmodium 
falciparum have been identified as important risk factors (3). Sporadic BL occurs 
worldwide, shows male preponderance, but more commonly involves the ileocecal region 
(mucosa, appendix, ascending colon), lymph nodes and, occasionally, the bone marrow, 
kidney, ovary and other miscellaneous regions (4). The peak age is early adolescence and 
young adulthood, but cases can occur at any age. The risk factors for sporadic BL have not 
been identified. Immunodeficiency-associated BL, which have been described mostly in 
countries in the West, occurs in the context of human immunodeficiency virus (HIV) and 
solid organ transplantation and, similar to endemic and sporadic BL, shows male 
predominance (1). Except for immunosuppression, the risk factors for immunodeficiency-
associated BL have not been identified. EBV is considered less important in both sporadic 
and immunodeficiency-associated BL because it is detected in at most 20% of cases in the 
former (5-8), and in about 30-40% of cases in the later.
We recently identified separate incidence peaks near 10, 40, and 70 years in BL cases in the 
United States in the general population (9) and in persons with AIDS (10). Similar, separate, 
incidence peaks were observed in BL cases from four continents, excluding the U.S.(11). 
Data from Africa were sparse or incomplete, the hypothesis that BL in Africa is multimodal 
could not be evaluated. Multiple incidence peaks of BL suggest BL with distinct etiology 
and/or biology, which may vary according to age. This reasoning is in keeping with 
conclusions drawn about Hodgkin lymphoma (12-14), whose multiple incidence peaks are 
generally accepted as epidemiologic evidence for Hodgkin lymphoma variants with distinct 
biology or etiology (12, 15). We investigated the hypothesis that BL in the U.S. may have 
distinct immunophenotype, molecular and viral profile, which varies with age, using tumors 
retrieved from residual tissue repositories (RTRs) and diagnostic referral centers located in 
three SEER population-based cancer registry areas that were reviewed centrally by 
experienced hematopathologists (BNN, LMW, and STP).
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Institutional Review Board Approvals
Institutional Review Boards at the University of Southern California, University of 
California at Los Angeles, University of Hawaii, University of Iowa, and Cedars Sinai 
Medical Center and at the National Institutes of Health gave ethical approval to conduct the 
study.
Selection of cases
Formalin-fixed paraffin embedded tissue (FFPET) for 81 cases diagnosed as BL between 
1979 and 2009 were retrieved from three SEER RTRs in Los Angeles County, Hawaii, and 
Iowa (16). A diagnosis of BL was based on morphology code 9687 in the International 
Classification of Diseases in Oncology, third edition, (ICD-O-3)(1). These cases were 
augmented with an additional 36 FFPET specimens diagnosed for BL cases at the University 
of California at Los Angeles (UCLA) or the City of Hope Cancer Center. Each case’s age, 
year of diagnosis, sex, and race/ethnicity (categorized as non-Hispanic white, Hispanic 
white, Black, and Asian/Native American) were compiled and computerized. HIV status 
was available for some cases. When not available, HIV status was coded as missing. Patient 
or hospital identifiers were not used in this study.
Pathology review of cases
Hematoxylin and eosin (H&E) and immunohistochemistry using monoclonal antibodies for 
CD20, CD3, Bcl-6, Bcl-2, Ki-67, (DAKO, Carpinteria, California) and CD10 (Novocastra, 
Bannockburn, Illinois) were performed on thin sections prepared from FFPET following 
standard procedures.
In-situ hybridization for EBV-encoded small ribonucleic acid (EBER) was performed 
(LMW) as previously described (17). This technique has 100% sensitivity for detecting 
EBER in Hodgkin lymphoma, thus a known EBER positive Hodgkin lymphoma case was 
included as a positive control (18). A poly-d(T) was included in tests as a control for total 
RNA preservation. Cases with adequate staining were classified as EBER positive if the 
nucleus of a tumor cell was stained dark blue or black, otherwise as negative.
Fluorescence in-situ hybridization (FISH) to detect rearrangement of MYC was performed 
using dual color fluorescent MYC break-apart probes (Abbott #32-191096: Abbot/Vysis, 
Downers Grove, IL, USA) following standard procedures (LMW). When hybridization was 
deemed adequate, the results were read and coded as negative or positive based on the 
fluorescent signal patterns (LMW). A minimum of 20 cell nuclei (five fields of 4 cells per 
field) were scored per slide. For negative cases, the entire tumor slide was evaluated again 
with a manual scope.
The stained sections were reviewed by three experienced lymphoma hematopathologists 
(BNN, LMW, and STP). A single hematopathologist (BNN) reviewed all the H&E stains for 
adequacy of diagnostic material, compatible histological features of BL and classified the 
cases as typical BL morphology or as compatible but variable or atypical BL. A qualitative 
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evaluation (positive or negative) was applied for immunohistochemistry results for CD10, 
CD20, Bcl-2 and Bcl-6 (19). A semi-quantitative evaluation was applied on the number of 
cells staining positive as a percent (%) of all malignant cells considered to have positive 
intensity pattern, results as follows: <10% (+), 10-50% (++), and >50% (+++) staining in 
tumor cells for the marker. For Ki-67, a similar semi-quantitative evaluation was as follows: 
<50% (+), 50-90% (++), 91-95% (+++), 96-99% or 100% (++++) of tumor cells.
Results of MYC and EBER FISH were reviewed by one hematopathologist (LMW) who 
recorded the result as positive or negative. These results were also reviewed by another 
hematopathologist (BNN) who combined them with the H&E and immunohistochemistry 
results and made a diagnosis according to the criteria established in the 2008 World Health 
Organization (WHO) classification of lymphoma(1). A case was diagnosed as BL when the 
lymphoma showed a diffuse and starry sky pattern under the microscope, and was composed 
of a monotonous hypercellular population of medium-sized lymphoid cells with round 
nuclei, open chromatin, multiple distinct nucleoli, moderate amounts of basophilic 
cytoplasm and frequent mitotic figures. The malignant cells were positive for CD10, CD20, 
Bcl-6, negative for Bcl-2, and had Ki-67 (proliferation activity). Some cases with variability 
in tumor cell morphology or absence of the typical immunoprofile were identified. These 
cases were jointly reviewed by two hematopathologists (BNN and STP), to make a 
consensus on the diagnosis.
Statistical analysis
Demographic and pathologic characteristics were analyzed using frequency tables, the Chi-
squared statistic for categorical variables and Student’s t-test for continuous variables. 
Although we have previously studied variation of BL across three age groups (0-19, 20-59, 
60+ years) (9, 10, 20), we split the middle age group into 2 groups of 20-34 years (young 
adults) and 35-59 year olds (older adults) to create four categories (0-19, 20-34, 35-59 and 
60+ years). This was done to ascertain differences in patterns in young adults, who may 
have had recent EBV or HIV infection, and in older adults, who may have had chronic EBV 
or HIV infection. Odds ratios (ORs) and 95% confidence intervals (CIs) for the association 
of HIV with EBER positivity in BL were estimated using unconditional logistic regression. 
Two-sided P-values of < 0.05 were considered statistically significant.
Results
Out of the 117 cases whose H&E slides were initially reviewed, 91 cases were confirmed as 
BL (Figure 1). The remaining 26 cases were excluded because of insufficient diagnostic 
tissue (n=10) or reclassification as other lymphoma subtypes after detailed review (n=16). 
The demographic characteristics of the 91 cases are described in Table 1.
Characteristics of BL cases
All 91 confirmed BL cases were positive for CD20, 98% were CD10 positive, 91% were 
Bcl-6 positive, and 92% were Bcl-2 negative. MYC gene rearrangement was positive in 89% 
(Table 2). Positivity for Bcl-6 and MYC rearrangement did not correlate with age (Table 3).
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Of the 91 BL cases, 19 did not have the immunoprofile of typical BL and hence were 
classified as not typical BL (Table 2). These 19 cases did not differ from the typical BL 
cases with respect to age (Table 3). Two of the 19 cases were CD10 negative and Bcl-2 
positive, but they had classic BL morphology and were positive for CD20, Bcl-6, 
Ki-67>90% and MYC. Five non-typical BL cases had Bcl-2 positivity (representative 
micrographs in Figure 2A-G), which may occur at low levels in BL (21). These five cases 
exhibited classic morphology and were positive for CD20, CD10, and Bcl-6, with a Ki-67 of 
90% to>99%. MYC rearrangement results were available for 2 of these cases and both were 
positive, but not in the remaining three cases. In 5 more cases Bcl-6 was un-evaluable 
(negative due to technical reasons), but they had the classic BL morphology, CD20 and 
CD10 positivity, Ki-67 >90%, and Bcl-2 negativity. In the remaining 7 non-typical BL 
cases, staining for Ki-67 and/or Bcl-6 were un-evaluable because these cases showed no 
internal positive staining, implying that the negative results were likely artifactual due to 
loss of antigenicity, the tissue fixative used, decalcification process or long duration of 
sample storage. However these 7 cases displayed classic morphology, were positive for 
CD20, CD10 and were BCL-2 negative, and hence classified as BL. In addition, in 5 of 
these 7 cases, MYC rearrangement by FISH was positive in all 5 cases.
EBER and HIV status in the BL cases
Overall, EBER positivity (Figure 2H) was found in 24 (29%) of 82 cases with complete 
EBER results, and the proportion varied according to age (Figure 3A, based on 74 cases 
whose age was known), race/ethnicity (Figure 3B), and HIV status (Figure 3C). Among 74 
cases with known age, the percentage of EBER positive cases increased from 13% (3/23) 
among cases aged 0-19 years to 55% (6/11) among those aged 20-34 years, and then 
decreased to 33% (8/24) among those aged 35-59 years and to 25% (4/16) in 60+ years and 
older (Pheterogeneity=0.08). Among 77 cases with both ethnicity and EBER results, EBER 
positivity was 56% (9/16) in Blacks/Hispanics and 21% (13/61) in the non-Hispanic/White/
Asian/Pacific Islanders (Pheterogeneity=0.006). Among 32 BL cases with HIV results, 18 were 
HIV negative and 14 were HIV positive. The 14 HIV positive cases were between ages 
20-59 years, representing 67% of the 21 BL cases in this age group with HIV results. EBER 
positivity was 64% (7/11) in the HIV positive cases and 22% (4/18) in the HIV negative 
cases (P=0.03, Figure 3C). The EBER positivity remained 64% among HIV positive cases 
in age group 20-59 years, but it was lower at 14% in the HIV negative cases. HIV positivity 
was associated with EBER positivity (OR 6.8, 95% CI 1.6-28.4) in analyses adjusting for 
age group. Adjusted for HIV status, age group was not independently associated with EBER 
positivity (P=0.16).
Bcl-2, EBER, HIV status and age in BL cases
Overall, Bcl-2 positivity by immunohistochemistry was low (8%, n=7), as expected, and did 
not differ by age group (Table 3, P=0.96). None of the Bcl-2 positive cases was positive for 
IgH@-BCL2 fusion signals by FISH, but 5 of 7 cases with interpretable results showed 
evidence of multiple copies of (polysomy) the IgH@ and/or BCL2 gene loci (data not 
shown). Bcl-2 and EBER positivity results were mutually exclusive; 10% (6/58) of EBER 
negative BL cases were Bcl-2 positive compared to 0% (0/24) among EBER positive cases 
(P=0.10). Similarly, Bcl-2 and HIV positivity results were also mutually exclusive; 22% 
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(4/18) of HIV negative cases were Bcl-2 positive compared to 0% (0/14) among HIV 
positive cases (P=0.09). All seven BL cases that were Bcl-2 positive tested negative for both 
viruses (P=0.03).
Discussion
We investigated the hypothesis that the morphology, immunophenotype, molecular, and 
viral (EBV and HIV) patterns of BL in the United States may vary with demographic 
characteristics. Our data suggest that one-third of BL tumors were EBV positive. EBV 
positivity in BL in the United States was strongly associated with ethnicity, HIV status, and, 
marginally associated with age group. These results confirm previous impressions that EBV 
is not implicated in the majority of BL in the general population in the United States. The 
distinct associations between EBV positive and EBV negative BL with demographic 
characteristics suggest EBV may be a marker of distinct BL entities, which may arise via 
distinct molecular pathways (22-25).
Our finding that some BL tumors were Bcl-2 protein positive is intriguing, but not new. The 
current criteria for diagnosing BL exclude tumors with strong Bcl-2 positivity (26, 27), but 
previous reports have noted Bcl-2 positivity in BL diagnosed after careful evaluation of all 
evidence (21, 28). Our results, based on careful evaluation using the WHO classification, 
expand on those results with the observation that the Bcl-2 positive tumors in our study were 
negative for both EBV and HIV. This finding might be due to chance or it may be a clue to 
differences in BL entities that arise and/or progress via distinct pathways that are influenced 
by abnormalities induced by viral co-factors or in host genes (29). The molecular 
mechanism for Bcl-2 expression in BL cases is uncertain, however, IgH@-BCL2 
translocations were not found in the cases. We note Bcl-2 protein expression can occur in 
the absence of BCL2 gene rearrangement(19) and is observed in many types of B and T cell 
lymphomas as well as in benign mantle cells, benign marginal zone B-cells, and benign 
small-T-cells (19). In keeping with these results, polysomy of the IgH@ and/or BCL2 gene 
loci might be related to Bcl-2 positivity as a secondary event.
The cases in our tissue study are similar in age to the 3058 cases in the SEER study where 
we reported trimodal incidence peaks in the United States (30). In both studies, cases aged 
0-19 years, 20-59 years, and 60+ years, contributed approximately 30%, 50% and 20%, 
respectively. The substantial proportion of BL among adults (20-59 years) is in keeping with 
the impact of HIV on BL. In our study, 67% of BL cases in the 20-59 year age group were 
HIV positive and is consistent with a substantial impact of HIV in this age group. In keeping 
with the large number of our cases from Los Angeles, which has a relatively high prevalence 
of HIV and contributed the majority of BL cases in the current series, our study may 
overestimate the proportion of BL due to HIV. An analysis of the United States HIV/AIDS 
Cancer Match Study, albeit based on cases not verified by hematopathologist review, 
estimated that about 20% of BL since 1980 could be attributed to HIV/AIDS (31).
Our finding that 29% of BL cases were EBER positive confirms the comparatively low 
prevalence of EBV in BL reported in the United States(5). EBV positivity was slightly 
higher in the present analysis than that reported in earlier case series (10-20%)(6-8), but 
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those studies were conducted before the HIV epidemic. Of interest, EBV positivity in BL 
bears some similarity to EBV positivity in Hodgkin lymphoma (32). In both conditions, 
EBV positivity is generally higher among African-Americans and Hispanic Whites than in 
non-Hispanic Whites or Asian/Pacific Islanders (32). In both, EBV positivity is also higher 
in HIV positive cases than in HIV negative cases (14). These similarities suggest that EBV 
infection is a co-factor for both tumors in these racial groups (33), and that EBV reactivation 
due to HIV-related immunosuppression is a risk factor for both tumors.
However, there are certain differences between BL and Hodgkin lymphoma. In BL, EBV 
positivity peaked among young adults, whereas in Hodgkin lymphoma, EBV positivity 
peaks among young children and elderly adults (32). These contrasting patterns in BL and 
Hodgkin lymphoma suggest that both primary EBV infection and EBV reactivation may 
influence the risk for Hodgkin lymphoma, while primary EBV may be more relevant for BL. 
As such, the peak of EBV positive Hodgkin lymphoma in young children is in keeping with 
the contribution of primary EBV at an early age, when the immune system is immature, 
whereas a peak in the elderly is in keeping with the contribution of reactivated latent EBV in 
the elderly (14), as immunity declines. In BL, EBV positivity peaks in young adults in 
keeping with a contribution from primary EBV infection among adolescents and young 
adulthoods. Thus, although EBV reactivation occurs in the elderly, it may not play an 
important role in BL in the elderly (14).
Taken together, our and other studies (9, 10, 20) suggest that BL is comprised of EBV 
positive and EBV negative entities. EBV positive and EBV negative BL is observed in HIV 
positive and negative individuals and at all ages, and in all races. The common abnormality 
in BL entities is hyper-proliferation of B-cells due to MYC deregulation, which is triggered 
by chromosomal translocations of the MYC oncogene on chromosome 8 (8q24) into the 
vicinity of the regulatory elements of one of the immunoglobulin heavy or light chains at 
chromosome positions 14q32, 2p12, or 22q11.2(34, 35). The strong proliferative signals 
induced by these translocations deregulate MYC (1) triggering strong apoptosis signals to 
protect the cell from progressing to malignancy (36, 37). We suggest that EBV positivity is a 
clue to different pathways initiated B cells take to progress to malignancy. In one instance, 
the cells may rely on viral factors, whereas in other instances, they may rely on 
abnormalities developed in host genes.
Strengths of this study include using population-based BL cases that were defined according 
to the current WHO classification system for lymphoma (1) after expert pathology review, 
which heretofore has not been done in most studies. To increase sample size, we included 
cases diagnosed up to 30 years ago. However, one of the drawbacks of using long-term 
archived specimens is loss of antigenicity, and the other is lack of HIV and demographic 
data, in some cases. For example, incomplete results in some of the non-typical BL cases 
(cases 6 and 7 in Table 2 lack results on MYC FISH) preclude firm conclusions as to 
whether these cases truly represent BL or the intermediate BL/DLBCL.
In conclusion, our findings confirm that EBV is not implicated in the majority of cases in the 
United States. EBV positivity is strongly associated with race and HIV status and marginally 
associated with age group. The distinct associations of EBV positive and EBV negative BL 
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with demographic and viral factors support the notion that EBV may be a marker of distinct 
BL entities, which may differ in biology and/or etiology.
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Flow diagram showing number of cases evaluated and the results of pathology evaluation at 
each stage.
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(A) Burkitt lymphoma cells showing hypermitotic activity (hematoxylineosin stain, 
magnification ×400). (B) CD20 immunostain showing strong membrane staining 
(magnification ×400). (C) CD10 immunostain showing strong membrane staining 
(magnification ×400). (D) Bcl-6 showing strong nuclear staining in the lymphoma cells 
(magnification ×400). (E) Ki-67 showing proliferation index > 99% (magnification ×400). 
(F) Positive dual color c-MYC gene break apart probe fluorescent in-situ hybridization 
(FISHba): A separate red and green signal indicates rearrangement of the MYC gene (see 
white arrow). A fused one orange/green (yellow) fused signal pattern indicates lack of 
rearrangement (magnification ×400). (G) Section showing cases with Bcl-2 positivity in the 
lymphoma cells. Note: all Bcl-2 positive cases were EBER negative (magnification ×20). 
(H) EBER in-situ hybridization showing strong nuclear staining in tumor cells 
(magnification ×400).
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Bar graph showing the percent of confirmed BL cases with EBV Early RNA protein 
(EBER) detected according to age group (A), race/ethnicity (B), and HIV status (C).
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Table 1
Demographic characteristics of confirmed Burkitt lymphoma cases
Characteristics Number of cases (%)
All subjects 91 (100)
Repository
 Los Angeles 54 (59)
 Hawaii 15 (16)
 Iowa 22 (24)
Diagnosis year
  1979 2 (2)
 1980-1989 14 (15)
 1990-1999 27 (30)
 2000-2009 42 (46)
 Missing 6 (7)
Sex
 Male 73 (80)
 Female 12 (13)
 Missing 6 (7)
Race
 Non-Hispanic White 51 (56)
 Black/African American 3 (3)
 Hispanic White 15 (16)
 Asian/Pacific Islander* 16 (18)
 Unknown/missing 6 (7)
Age at diagnosis, years
 0-19 24 (26)
 20-34 14 (15)
 35-59 26 (29)
 60+ 17 (19)
 Missing± 10 (11)
HIV status
 Negative 18 (20)
 Positive 14 (15)
 Unknown/missing 59 (65)
*
or American Indian or Alaska Native
±
includes 4 cases whose age was provided as in range 20-59 years
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